BetterInvesting™ Magazine Update on Vertiv Holdings Co. (NYSE: VRT) and CVS Health Corp. (NYSE: CVS)
September 30, 2025Vertiv Holdings Co.’s recent report has investors wondering if the company’s stock is fairly valued. Or is it in the buy range? As such, the Editorial Advisory and Securities Review Committee of BetterInvesting Magazine consider Vertiv Holdings Co. (NYSE: VRT) as worthy of further study and has named the company its “Stock to Study” for the December 2025 issue for investors’ informational and educational use.
The fundamental data is eye-opening; investors can view Vertiv’s sales, earnings, pre-tax profit, return on equity, and more all on one page, courtesy of the National Association of Investors Corp., at: https://ssg.betterinvesting.org/study/ssgplus/?studyid=17125916.
A full report on Vertiv will appear in the December 2025 issue of BetterInvesting Magazine.
The same issue of BetterInvesting Magazine will also include a fundamental review of CVS Health Corp. (NYSE: CVS), which the independent Editorial Advisory and Securities Review Committee believes is worthy of further study from an undervalued perspective.
Committee members are Daniel J. Boyle, CFA; Marisa Bradbury, CFA; Philip Keating, CFA; Anne Nichols, CFA; and Dan Rutter, CFA.
Doron P. Levin, an editor of the magazine, serves as the committee’s chairperson.
Securities mentioned are for study and presented for educational purposes only. They are not to be considered as endorsed or recommended for purchase by NAIC/BetterInvesting. Investors should conduct their own review and analysis of any company of interest using the Stock Selection Guide before making an investment decision.
